Tyrosine kinase inhibitorFDA-approvedFirst-line
Vizimpro
Generic name: dacomitinib
How it works
Blocks the activity of multiple proteins involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— All patients
Efficacy
In clinical trials, dacomitinib improved response rates and progression-free survival in patients with NSCLC, compared to chemotherapy.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Dacomitinib Shows Promise for Lung Cancer Patients Resistant to Other Treatments | Lung Cancer | observational | The objective response rate was 33.3%, and the disease control rate was 78.6%. | Source → |
| Testing Treatments for EGFR-Mutated Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Low-Dose Dacomitinib Shows Promise for Lung Cancer Patients | Lung Cancer | observational | The objective response rate in the low-dose dacomitinib group was 67.7%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.